Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-finding study of KEM2104 cataplasm for knee osteoarthritis
CTR20263437Phase 2Active
- Sponsor
- Jingyi Pharma
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of KEM2104 in knee osteoarthritis (OA), sponsored by Jingyi Pharma. Started Sep 2026; status: active.
02
Drugs
KEM2104
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on CTR20263437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263437.